Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 11 Neoplasms 5 Parasomnias 4 Depression 3 Weight Loss 2 Tuberous Sclerosis 2 Smith-Magenis Syndrome 2 Sleep Wake Disorders 2 Polycystic Ovary Syndrome 2 Pain 2 Lung Neoplasms 2 Fatigue 2 Cachexia 2 Autism Spectrum Disorder 2 Anxiety Disorders 2 Angelman Syndrome 2 Uveal Melanoma 1 Squamous Cell Carcinoma of Head and Neck 1 Sleep Disorders, Circadian Rhythm 1 Relapsed Malignant Solid Tumor 1 Radiodermatitis 1 Radiation Injuries 1 Quality of Life 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Neoplasm Metastasis 1 Melanoma 1 Leukoplakia, Oral 1 Keratosis, Actinic 1 Hematologic Neoplasms 1 Head and Neck Neoplasms 1

Interventions

Ipilimumab 29 Nivolumab 23 pembrolizumab 14 incomplete Freund's adjuvant 10 Cyclophosphamide 10 Interleukin-2 9 Melphalan 8 CTLA-4 Antigen 8 sargramostim 7 Temozolomide 7 MART-1 Antigen 7 Dacarbazine 7 tebentafusp 6 Ranibizumab 6 montanide ISA 51 5 fludarabine phosphate 5 fludarabine 5 Sunitinib 5 Radiosurgery 5 Carboplatin 5 Bevacizumab 5 aldesleukin 4 aflibercept 4 Magnetic Resonance Spectroscopy 4 Granulocyte-Macrophage Colony-Stimulating Factor 4 Blood Specimen Collection 4 Biopsy 4 trametinib 3 sotrastaurin 3 relatlimab 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Uveal Melanoma × Melatonin × Clear all

NCT05502900 2025-05-15

AMUM

St. Erik Eye Hospital

Phase 3 Recruiting

Uveal Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡